Market Analysis: Generics Will Constrain Growth of Hospital-Treated MRSA Drugs
Most emerging therapies target skin infections (October 17)
Decision Resources, a research and advisory firm located in Burlington, Mass., finds that the hospital-treated methicillin-resistant Staphylococcus aureus (HT-MRSA) drug market will grow modestly over the next decade from approximately $900 million in 2012 to $1 billion in 2022 in the U.S., Europe, and Japan.
The new report also finds that as many as eight new agents with activity against MRSA are expected to launch within the next 10 years. Among these drugs, tedizolid (Cubist), a second-generation intravenous (IV)/oral oxazolidinone, is best positioned for commercial success because of its high efficacy against MRSA, its convenient once-daily dosing, and its ability to achieve clinical cure with a shorter course of therapy compared with linezolid (Zyvox, Pfizer).
While the uptake of tedizolid for HT-MRSA infections will help drive growth in the HT-MRSA market, the entry of generic formulations of current leading therapies — linezolid and daptomycin (Cubicin, Cubist/Novartis/Merck) — will constrain growth. In 2012, sales of linezolid and daptomycin accounted for 70% of HT-MRSA major-market sales. However, because of generic erosion, by 2022 sales of these therapies will comprise only 40% of the HT-MRSA market, the report says.
The findings also show that the HT-MRSA market is becoming increasingly crowded, as most of the emerging therapies target the complicated skin and skin-structure infection (cSSSI) segment of this market. As a result, new agents will need to clearly differentiate themselves from current and emerging therapies by targeting underserved indications, such as nosocomial pneumonia and bloodstream infections, in order to find favorable uptake and formulary positioning in this competitive market.
In addition, hospitals are seeking to contain health care costs by transitioning patients toward early hospital discharge. This practice will drive the uptake of agents with IV and oral formulations that permit step-down therapy (such as BC-3781 [Nabriva], eravacycline [Tetraphase], delafloxacin [Melinta], and tedizolid [Melinta]), as well as IV agents with once-weekly dosing schemes (such as dalbavancin [Durata] and oritavancin [Medicines Company]).
Source: Decision Resources; October 17, 2013.